Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis

• Published in: Journal of clinical medicine 2023-12, Vol.12 (24), p.7578
• Main Authors: Hanafy, Amr Shaaban, Embaby, Ahmed, Salem, Sara Mohamed, Behiry, Ahmed, Ebrahim, Hasnaa Ali, Elkattawy, Hany Ahmed, Abed, Sally Yussef, Almadani, Moneer E, El-Sherbiny, Mohamad
• Format: Article
• Language: English
• Subjects: Adenoviruses; Adverse and side effects; Antigens; Ascites; Care and treatment; Clinical medicine; Complications and side effects; COVID-19 vaccines; Drug dosages; Drugs; Hepatitis B; Hepatitis C; Hepatology; Infections; Lipids; Liver cancer; Liver cirrhosis; Liver diseases; mRNA vaccines; Nanoparticles; Patient outcomes; Patients; Proteins; Severe acute respiratory syndrome coronavirus 2; Ultrasonic imaging; Viruses
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12247578

COVID-19 infections accelerate liver decompensation and serious liver-related co-morbidities. The aim is to evaluate the safety and impact of COVID vaccines on hepatic disease progression in patients with advanced liver disease and to identify parameters that predict the occurrence of complications. The study involved 70 patients with advanced liver disease who were vaccinated with different COVID vaccines from January 2021 to April 2022. They were evaluated clinically. The laboratory investigation included a complete blood count, liver and kidney function tests, calculation of CTP and MELD scores, plasma levels of ammonia, abdominal ultrasound, and upper GI endoscopy. Twenty patients had experienced complications 64 ± 12 days from the last dose of a vaccination. Twenty patients (28.6%) developed hepatic decompensation and hypothyroidism ( = 11, 15.7%), and five (7.14%) patients developed splanchnic thrombosis. There were no COVID-19 reinfections except for two patients who received Sinopharm and developed vaccine-associated enhanced disease (2.9%). Complications after COVID vaccinations were correlated with ALT (r = 0.279, = 0.019), serum sodium (r = -0.30, = 0.005), creatinine (r = 0.303, = 0.011), liver volume (LV) (r = -0.640, = 0.000), and MELD score (r = 0.439, = 0.000). Multivariate logistic regression revealed that LV is the only independent predictor ( = 0.001). LV ≤ 682.3 has a sensitivity of 95.24% and a specificity of 85.71% in predicting complications with an AUC of 0.935, < 0.001. In conclusion, the hepatic reserve and prognosis in liver cirrhosis should be evaluated prior to COVID vaccinations using the MELD score and liver volume as promising risk stratification criteria. In summary, the research proposes a novel triaging strategy that involves utilizing the MELD score and liver volume as risk stratification parameters of the hepatic reserve and prognosis of advanced liver cirrhosis prior to COVID immunization to determine who should not receive a COVID vaccination.